Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting

Antiviral Therapy

Volumn 19, Issue 3, 2014, Pages 319-324

  Monforte, Antonella D'Arminio ^a   Gianotti, Nicola ^b   Cozzi Lepri, Alessandro ^c   Pinnetti, Carmela ^d   Andreoni, Massimo ^e   Di Perri, Giovanni ^f   Galli, Massimo ^g   Poli, Andrea ^b   Costantini, Andrea ^h   Orofino, Giancarlo ⁱ   Maggiolo, Franco ^j   Mazzarello, Giovanni ^k   Celesia, Benedetto Maurizio ^l   Luciani, Filippo ^m   Lazzarin, Adriano ^b,n   Sighinolfi, Laura ^o   Rizzardini, Giuliano ^p   Bonfanti, Paolo ^q   Perno, Carlo Federico ^e   Antinori, Andrea ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

ⁱ AMEDEO DI SAVOIA HOSPITAL   (Italy)

^j Spedali Riuniti   (Italy)

^k UNIVERSITY OF GENOA   (Italy)

^l UNIVERSITY OF CATANIA   (Italy)

^m Annunziata Hospital   (Italy)

ⁿ VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^o UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^p UNIVERSITY OF MILAN   (Italy)

^q A MANZONI HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR PLUS RITONAVIR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOPINAVIR; RITONAVIR;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MONOTHERAPY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; VIRUS LOAD; ADDICTION; BLOOD; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; HEPACIVIRUS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; TIME; VIROLOGY;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; SUBSTANCE-RELATED DISORDERS; TIME FACTORS; VIRAL LOAD;

EID: 84902649144     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2687     Document Type: Article

References (10)

1. Pulido F, Arribas JR, Delgado R, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008; 22:F1-F9.
2. Cameron DW, Da Silva BA, Arribas JR, et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 2008; 198:234-240.
3. Cahn P, Montaner J, Junod P, et al. Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV individuals on the 1st PI-based regimen. PLoS ONE 2011; 6:e23726.
4. Cooper C, La Porte C, Tossonian H, Sampalis J, Ackad N, Conway B. A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected individuals: the MONOCO study. HIV Clin Trials 2012; 13:179-188.
5. d'Arminio Monforte A, Cozzi Lepri A, Rezza G, et al . Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive individuals. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Individuals. AIDS 2000; 14:499-507.
6. Johnson VA, Calvez V, Gunthard HF, et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 2013; 21:6-14.
7. Rosenblum M, Deeks SG, Van der Laan M, Bangsberg DR. The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS ONE 2009; 4:e7196.
8. Guiguet M, Ghosn J, Duvivier C, et al. Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study. AIDS 2012; 26:2345-2350.
9. Pulido F, Pérez-Valero I, Delgado R, et al. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther 2009; 14:195-201.
10. Gutmann C, Cusini A, Günthard HF, et al. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 2010; 24: 2347-2354.